Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

260
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
260
Tissue Transplantation01:24

Tissue Transplantation

271
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
271
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

3.0K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.0K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.0K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.0K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.1K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.1K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Phase I/II Trial of the FLT3 Kinase Inhibitor XY0206 in Patients With Relapsed/Refractory Acute Myeloid Leukemia.

European journal of haematology·2026
Same author

Epigenetic insights into minimal residual disease detection in cancer.

Genes & diseases·2026
Same author

Analysis of Linezolid Blood Concentration and Prediction Modeling of Thrombocytopenia in Orthopedic Patients.

Surgical infections·2025
Same author

Optimizing RNA quality in cryopreserved tissues without preservatives: impact of preservatives, thawing methods and tissue aliquot sizes.

BMC biotechnology·2025
Same author

Combination Therapy with Romiplostim, Danazol, and a Thrombopoietin Receptor Agonist for Immune Restoration in Chronic Refractory Immune Thrombocytopenia: A Case Series.

ImmunoTargets and therapy·2025
Same author

Extranodal diffuse large B-cell lymphoma: Clinical and molecular insights with survival outcomes from the multicenter EXPECT study.

Cancer communications (London, England)·2025

相关实验视频

Updated: May 7, 2025

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
03:40

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

844

血造干细胞微移植:当前情况和挑战

Zhengyang Li1, Yuanyuan Yang1, Hongwei Peng2

  • 1Center of Hematology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.

Therapeutic advances in hematology
|January 6, 2025
PubMed
概括

血造干细胞微移植 (MST) 通过结合治疗来改善存活率和减少移植对宿主疾病 (GVHD) 为血液恶性瘤提供了一种新的方法. 这种策略增强了移植与瘤的反应,同时保持了免疫功能.

关键词:
在GVHD中,GVHD是指GVHD在MST上,我们可以使用MST.血液学的恶性瘤.造血干细胞是血液形成的干细胞.免疫疗法 免疫疗法微移植是一种微移植.

更多相关视频

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
05:32

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

364
Isolation and Transplantation of Hematopoietic Stem Cells HSCs
20:38

Isolation and Transplantation of Hematopoietic Stem Cells HSCs

Published on: February 25, 2007

23.6K

相关实验视频

Last Updated: May 7, 2025

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
03:40

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

844
In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
05:32

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

364
Isolation and Transplantation of Hematopoietic Stem Cells HSCs
20:38

Isolation and Transplantation of Hematopoietic Stem Cells HSCs

Published on: February 25, 2007

23.6K

科学领域:

  • 血液学 血液学 血液学
  • 免疫学 免疫学 免疫学
  • 在瘤学瘤学.

背景情况:

  • 全基血造干细胞移植 (allo-HSCT) 对血液恶性瘤有效,但受移植对宿主疾病 (GVHD) 的限制,这是死亡的主要原因.
  • 尽管如此,GVHD仍然是alo-HSCT的重要障碍,影响患者的治疗结果和生活质量.

研究的目的:

  • 审查血液造血干细胞微移植 (MST) 的机制,临床应用和挑战.
  • 探索MST的潜力,通过减少GVHD和增强移植与瘤 (GVT) 反应来改善血液恶性瘤的治疗.

主要方法:

  • 对血液恶性瘤中MST现有文献的综述.
  • 对MST化学疗法,-HSCT和细胞免疫疗法的协同作用组合的分析.

主要成果:

  • MST在血液性恶性瘤中表现出有希望的结果,包括改善完全缓解,整体存活率和无进展存活率.
  • MST促进了造血的恢复,降低了感染风险,并显著降低了GVHD的发生率.
  • 这种方法旨在保持患者的免疫功能,并促进微化学反应,以获得强烈的GVT反应.

结论:

  • MST是一种新的治疗策略,有可能克服传统all-HSCT的局限性.
  • 进一步了解MST机制可以提高其临床实用性,并将其整合到标准的癌症治疗方案中.